Kura Oncology (NASDAQ:KURA) Stock Price Down 5.8% - What's Next?

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) were down 5.8% during trading on Tuesday . The stock traded as low as $7.06 and last traded at $6.82. Approximately 57,345 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 1,551,308 shares. The stock had previously closed at $7.24.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on KURA shares. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Scotiabank reduced their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. Finally, Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.50.

Kura Oncology Trading Down 3.0 %

The firm has a fifty day moving average of $7.97 and a two-hundred day moving average of $13.20. The company has a market cap of $566.90 million, a PE ratio of -2.97 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Remove Ads

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analysts' expectations of $57.96 million. As a group, sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last 90 days. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC boosted its position in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares during the last quarter. Harbor Advisors LLC bought a new stake in Kura Oncology during the fourth quarter valued at approximately $87,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology in the 4th quarter worth approximately $90,000. Corton Capital Inc. bought a new position in shares of Kura Oncology in the 4th quarter worth $99,000. Finally, Optimize Financial Inc bought a new position in shares of Kura Oncology in the 4th quarter worth $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.